galidesivir + placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
28
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Marburg Virus Disease
Conditions
Marburg Virus Disease
Trial Timeline
Dec 10, 2018 → Apr 30, 2019
NCT ID
NCT03800173About galidesivir + placebo
galidesivir + placebo is a phase 1 stage product being developed by BioCryst Pharmaceuticals for Marburg Virus Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03800173. Target conditions include Marburg Virus Disease.
Hype Score Breakdown
Clinical
10
Activity
5
Company
5
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03891420 | Phase 1 | Terminated |
| NCT03800173 | Phase 1 | Completed |
Competing Products
2 competing products in Marburg Virus Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| AVI-7288 | United Therapeutics | Phase 1 | 30 |
| AVI-6003 + Placebo | United Therapeutics | Phase 1 | 30 |